Benzinga | Jun 2, 2021 09:15AM EDT

BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients

* BriaCell Therapeutics Corp (NASDAQ:BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients.

* These women were treated with BriaCell's lead candidate, Bria-IMT, as monotherapy, and also in combination with checkpoint inhibitors, including Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) and Incyte Corporation's (NASDAQ:INCY) retifanlimab.

* 12 months of average overall survival benefit was observed, including 13.4 months in patients with 2+ human leukocyte antigen (HLA) matches and 12.5 months in patients with Grade 1/2 tumors.

* Top Responder achieved 21.4 months survival plus 100% resolution of 'eye-bulging' orbital tumor.

* It compares to 7.2-9.8 months survival in historical comparison treatment trials.

* Price Action: BCTX shares are up 104.1% at $6.50 during the premarket session on the last check Wednesday.